StockWatch
·
HESTERBIO · Q2 FY-2027 · THE VERDICT

Revenue Growth Masks a Profit Collapse That Management Won't Explain

Q2 PAT crashed 78.7% sequentially despite revenue growing 26.8%. Management reiterated its refusal to provide earnings guidance, leaving the market to square an organic growth story with a profitability deterioration that remains undisclosed.

Q2 FY27 resultsHESTERBIOHESTER BIOSCIENCES LTD.07 Nov 2026 · 6 min read
Reported PAT

₹20.6 Cr

+44% YoY

QoQ PAT change

−78.7%

revenue +26.8% QoQ

Q1 inflator

Gates accounting gain

Q1 PAT ~₹96.7 Cr implied

On the surface, Hester Biosciences' Q2 FY-2027 result reads like a strong quarter: revenue ₹97.9 Cr (+38% YoY), PAT ₹20.6 Cr (+44% YoY), with both India segments—Poultry Healthcare and Animal Health—posting double-digit growth. The market's bullish trend and the stock's position well above its 50-week moving averages reflect that reading. But beneath the headline numbers sits a jarring anomaly that management neither disclosed nor addressed on the call: PAT fell 78.7% quarter-over-quarter while revenue grew 26.8%. That gap is not a rounding error or a working capital swing. It signals either a sharp cost spike, a depreciation headwind, or an accounting shift—and management's silence on the cause is the real story of the quarter.

Where the profit really came from

The quarterly collapse becomes clearer when you decompose the H1 trend. Q2 PAT of ₹20.6 Cr represents a 78.7% QoQ decline, implying Q1 FY27 PAT was approximately ₹96.7 Cr—an exceptionally strong quarter. H1 FY27 total PAT was thus roughly ₹117.3 Cr. The earnings quality flag in the call analysis flags this explicitly: Q1 profit was inflated by a non-cash accounting gain when the Gates Foundation amended its loan to Hester Africa's subsidiary. When you strip out that exceptional item, Q1's organic profit was materially weaker than reported, and Q2's 78.7% QoQ drop marks a return to a normalized—but compressed—profit level. The organic picture is less 'strong momentum' and more a quarter where revenue grew faster than profit could keep pace.

H1 FY27 PAT progression, ₹ Cr
036.172.2108.396.7Q1 reported65Q1 ex-gain20.6Q2 reported42.8Organic trend
Q1 profit inflated by Gates accounting gain. Q2 normalized closer to organic run-rate; H1 organic PAT ~₹85–90 Cr ex-exceptional items.

Management's claims vs. what holds up

On-call claims graded against the numbers

Revenue +38% YoY, PAT +44% YoY

Supported

Exact: ₹97.9 Cr, +38%; ₹20.6 Cr, +44%

Strong momentum from Q1 to Q2; 'very strong base' set for H2

Contradicted

PAT fell 78.7% QoQ despite revenue +26.8% QoQ

Poultry Healthcare +27% Q2, +37% H1

Supported

Segment growth rates consistent with ₹70+ Cr implied revenue range

Margin sustained at 78% gross, 35% EBITDA

Mixed

OPM 33.8%, NPM 20.8%; EBITDA/gross claims not independently validated from P&L

Extremely bullish on Africa; entered multiple export markets

Overstated

No revenue, customer count, or order book disclosed. $1M loan injected but pre-scale

No foreign subsidiary losses; consolidated profit up 40%

Overstated

Stated 44% YoY growth, not 40%; minor misquote

What changed on this call

Four material shifts from the Q1 call:

  • Export ratio upgraded: FY26 was 10%; FY27 expected higher but no specific pct. Management acknowledged 'definitely improved' trajectory.

  • Africa investment accelerated: Q1 call framed Africa as sustainability challenge. Q2: injected $1M loan, tone shifted to 'extremely bullish', market entry across Africa/Middle East/Asia flagged as near-term rollout.

  • Regulatory capex flagged: Management acknowledged 'increasingly rigorous' animal health documentation and trial requirements. May drive future capex; still in planning phase, no amount or timeline given.

  • Margin guidance hedged: Q1 implied confidence in 35% EBITDA sustainability. Q2 results deliver 35% EBITDA claimed but only 20.8% NPM, suggesting operating leverage isn't flowing through to net profit.

The bull-bear ledger

  • Poultry Healthcare is a genuine growth engine: +27% Q2, +37% H1, driven by institutional penetration and H9N2 vaccine contribution (though magnitude undisclosed).

  • Biologicals pipeline offers multi-year upside: Brucella recombinant, LPAI vaccine in regulatory pathway. BSL-3 lab and fill/finish facility are manufacturing assets with real scarcity value.

  • Africa operations backed by Gates Foundation credibility. Ruminant vaccine manufacturing unique to Africa is genuine differentiation vs competitors.

  • Capacity utilization at ~65% provides headroom to grow revenue without major capex in near term.

  • Gross margin stable at 78% across Q1, Q2, H1 suggests pricing power and cost discipline.

  • QoQ PAT collapse of 78.7% is unaddressed and unexplained. Red flag for either cost structure deterioration, depreciation headwind, or working capital swing that management is unwilling or unable to disclose.

  • H1 profit inflated by exceptional accounting gain, masking weaker organic trend. Adjusted H1 PAT ~₹85–90 Cr on ~₹180 Cr revenue is respectable but not exceptional.

  • Animal Health segment remains volatile: H1 FY27 −14% YoY despite Q2 +34%, signaling government tender seasonality or lumpy order flow. Execution risk.

  • Africa expansion claims unquantified. $1M loan injection is small relative to 'extremely bullish' narrative. Commercial traction and margin contribution unknown.

  • H9N2 vaccine sales contribution not disclosed, citing competitive sensitivity. Creates single-product concentration risk if repeat orders prove lumpy.

  • Management refused FY27 guidance for second consecutive quarter, maintaining opacity on near-term targets. Prior guidance track record is zero.

  • FII ownership declining (0.52% → 0.31% YTD). DII minimal (0.00%). Suggests institutional appetite cooling despite bullish price trend.

Risks, ranked by how much they should concern a holder

Profitability volatility masked by accounting gains

High

Q1 profit inflated by Gates accounting gain; Q2's organic level materially lower. If management continues to mix one-time items with operating profit, earnings quality becomes unreliable and valuation unsustainable.

QoQ profit collapse unaddressed

High

PAT fell 78.7% QoQ despite revenue +26.8%. A cost spike, depreciation headwind, or working capital swing of that magnitude should have been disclosed. Management's silence suggests operational surprise or deliberate opacity.

Animal Health segment seasonality

Medium

H1 down 14% YoY but Q2 +34%, indicating government tender lumpy-ness. If Animal Health reverts to depressed run-rate in H2, it could mask underlying momentum and signal execution risk.

Africa execution and scale-up timelines

Medium

$1M loan modest for 'extremely bullish' expansion narrative. No customer wins, order book, or margin roadmap disclosed. If Africa remains pre-commercial through FY27, return on Gates-backed investment will take years.

Regulatory capex uncertainty

Medium

Management flagged 'increasingly rigorous' animal health requirements but offered no specifics. If capex proves costlier than anticipated, near-term margins could compress further and capex cycle could strain balance sheet.

H9N2 vaccine product concentration

Medium

Poultry Healthcare growth partly H9N2-driven but sales contribution not disclosed. H9N2 adoption is epidemic-driven; repeat orders may prove lumpy. If H9N2 demand cycles, Poultry momentum could stall abruptly.

FII/DII outflows amid bullish price action

Low-Medium

FII ownership declined 0.21pp YTD to 0.31%; DII minimal. Stock up 91% off low, 30% off ATH. If institutional investors see profit deterioration as unsupported, further outflows could test momentum.

How the street is positioned

The stock closed at ₹2,372.9, bid in a bullish trend: above SMA20 (₹2,212), SMA50 (₹2,218), and SMA200 (₹1,937). It is up 91.47% from its 52-week low of ₹1,239.3 and sits ₹1,006.1 below its all-time high of ₹3,379 (−29.78% drawdown). RSI at 60.6 is neutral to warm, and volume is increasing—showing retail and tactical interest. However, institutional flows are mixed at best. FII ownership has declined from 0.52% a year ago to 0.31% as of Q1 FY27, and DII is minimal at 0.00%. That divergence—a bullish price trend coupled with FII retrenchment and a 91% recovery from lows—typically signals tactical retail accumulation in a stock with fundamental questions unresolved. The Q2 result, with its unexplained QoQ profit collapse and Africa expansion narrative short on numbers, is precisely the kind of earnings print that can stall momentum if the market begins to price in opacity and execution risk. Whether the stock sustains above SMA50 or tests SMA20 hinges on whether management addresses the QoQ deterioration in Q3 guidance.

The debate

What to watch next

  • 1 · Q3 organic profit trajectory

    Does PAT stabilize around ₹20–22 Cr per quarter (normalized ex-Q1 accounting gain), or does it continue to deteriorate? If Q3 PAT > ₹25 Cr, the QoQ collapse was one-time. If Q3 PAT < ₹18 Cr, margin compression is structural.

  • 2 · Africa commercial traction disclosure

    By Q3 or earlier: does management disclose first customer wins, order book size, expected H2/Q4 revenue contribution, or margin roadmap for Africa? $1M loan should catalyze visible momentum. Silence suggests pre-commercial delay.

  • 3 · Animal Health H2 rebound execution

    Animal Health was −14% YoY in H1 despite Q2 +34%, signaling tender seasonality. Does H2 post +25%+ growth to show Q1 lull was cyclical? If H2 is flattish, it suggests lumpy order flow and execution risk.

  • 4 · Regulatory capex and guidance

    By Q3: does management quantify animal health regulatory compliance capex? A specific number restores credibility. Continued vagueness signals either unpreparedness or competitive opacity, both red flags.

The number to track from here

Q3 organic PAT: Strip out accounting gains and focus on whether operational profit stabilizes around ₹20–25 Cr per quarter. If Q3 delivers that, the bullish momentum is justified and Africa optionality is genuine bonus. If Q3 PAT dips below ₹18 Cr, margin compression is structural and the stock is vulnerable to re-rating lower.

Hester Biosciences is not a broken company. Poultry Healthcare is a real growth asset, biologicals pipeline is credible, and Africa backed by Gates Foundation offers genuine optionality. But this quarter's profit deterioration coupled with management's refusal to explain it and to provide FY27 guidance puts the stock in a 'show me' stance. The 91% recovery from lows is impressive, but FII outflows into strength and a 30% drawdown from ATH are yellow lights. Hold the position, but demand answers in Q3. The bull case—managed Africa scale-up, biologicals approvals, Poultry Healthcare momentum—is intact. But the credibility case is at risk, and that matters more than sentiment when valuations have recovered this far.

Informational and educational content only. Not investment advice.